Teva Confirms Denosumab Is Part Of Its Biosimilar Pipeline

Prolia Biosimilar Asset Is In Phase III Development

 
• By Dean Rudge
Clinical_Trial_Tablet
Teva estimates study completion in December 2023 • Source: Shutterstock

More from Biosimilars

More from Products